Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol vs febuxostat for reduction of serum uric acid in hyperuricemia
IRCT20251109067932N2Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of allopurinol and febuxostat in hyperuricemia (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Change in serum uric acid. Started Dec 2025; status: completed.
02
Drugs
allopurinolfebuxostat
03
Conditions
hyperuricemia
Beyond the preview
Go deeper on IRCT20251109067932N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251109067932N2.